[HTML][HTML] Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
R Dziadziuszko, J Jassem - Annals of Oncology, 2012 - Elsevier
Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients
for almost a decade. Current knowledge on their role in the first or subsequent lines of …
for almost a decade. Current knowledge on their role in the first or subsequent lines of …
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story
LV Sequist, TJ Lynch - Annu. Rev. Med., 2008 - annualreviews.org
Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on
the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also …
the treatment of non–small cell lung cancer (NSCLC). The use of these drugs has also …
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer
JE Dowell, JD Minna - Nature Clinical Practice Oncology, 2006 - nature.com
Although the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib can produce dramatic and durable tumor responses, not all patients with non-small …
erlotinib can produce dramatic and durable tumor responses, not all patients with non-small …
EGFR inhibitors: what have we learned from the treatment of lung cancer?
G Giaccone, JA Rodriguez - Nature Clinical Practice Oncology, 2005 - nature.com
Tyrosine kinase inhibitors directed against the epidermal growth factor receptor (EGFR) are
the first molecular-targeted agents to be approved in the US and other countries for the …
the first molecular-targeted agents to be approved in the US and other countries for the …
The role of epidermal growth factor receptor in advanced non‐small cell lung carcinoma
PA Jänne - Annals of medicine, 2003 - Taylor & Francis
Chemotherapy is the standard of care for patients with advanced non‐small cell lung cancer
(NSCLC). Over the past 20 years, advances in chemotherapy have shown minimal …
(NSCLC). Over the past 20 years, advances in chemotherapy have shown minimal …
Epidermal growth factor receptor inhibitors in lung cancer therapy
JJ Laskin, AB Sandler - Seminars in Respiratory and Critical …, 2004 - thieme-connect.com
Over the past decade our evolving knowledge and understanding of cancer biology has
allowed rapid progression in the development of targeted cancer therapy. Improving lung …
allowed rapid progression in the development of targeted cancer therapy. Improving lung …
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
AF Gazdar - Cancer and Metastasis Reviews, 2010 - Springer
Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the USA
and worldwide. Most patients present with advanced disease, and treatment options for …
and worldwide. Most patients present with advanced disease, and treatment options for …
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists
GA Silvestri, MP Rivera - Chest, 2005 - Elsevier
Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …
The role of EGFR inhibition in the treatment of non-small cell lung cancer
M Ray, R Salgia, EE Vokes - The oncologist, 2009 - academic.oup.com
The identification of certain molecular mechanisms underlying lung carcinogenesis and
progression has led to the development of targeted agents against different families of …
progression has led to the development of targeted agents against different families of …
EGFR tyrosine kinase inhibitors: difference in efficacy and resistance
KW Robinson, AB Sandler - Current oncology reports, 2013 - Springer
Lung cancer will be diagnosed in 230,000 patients in the US in 2013. Adenocarcinoma will
be the most common histology, and 10% of lung cancers will be diagnosed in never or …
be the most common histology, and 10% of lung cancers will be diagnosed in never or …